<html lang="en">

<head>
  <title>Community Acquired Pneumonia</title>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width,initial-scale=1.0" />
  <link rel="stylesheet" href="cpgPedEr.css" />

</head>

<body>
  <div id="header-container"></div>
  <header class="page-header">Community Acquired Pneumonia</header>

  <div class="container">
    <p class="cpg-headers">DEFINITION</p>
    <p class="cpg-text">
      <span><b>Pneumonia:</b> An inflammation of the lung parenchyma caused by
        microorganisms, <br> noninfectious causes include aspiration (of food or
        gastric acid, foreign bodies, hydrocarbons, and lipoid substances),
        hypersensitivity reactions, and drug- or radiation-induced
        pneumonitis</span>
      <br>
      <br>
      <span><b>Community-acquired pneumonia (CAP):</b> An acute pulmonary
        infection in a previously healthy individual acquired in the
        community</span>
    </p>

    <div class="border-btm"></div>

    <p class="cpg-headers">MOST COMMON MICROORGANISMS OF CAP</p>

    <table class="cpg-table" id="capMicroOrg">
      <tr style="background: #c9c9c9">
        <th>Age</th>
        <th>Microorganism</th>
      </tr>
      <tr>
        <td>0-3 mo</td>
        <td>
          Group B streptococcus <br />
          Gram-negative bacteria <br />Streptococcus pneumonia <br />Viruses
          15-30 %
        </td>
      </tr>
      <tr>
        <td>3 months- 5 years</td>
        <td>Viruses 50-60%</td>
      </tr>
      <tr>
        <td>> 5 years</td>
        <td>Mycoplasma pneumoniae and Chlamydophila</td>
      </tr>
    </table>
    <br />

    <div class="border-btm"></div>

    <p class="cpg-headers">CLINICAL MANIFESTATIONS</p>
    <ul>
      <li>
        Fever, cough, tachypnea, increased work of breathing (e.g., nasal
        flaring in infants, retractions) and hypoxia
      </li>
      <li>
        <b>Tachypnea</b> is more sensitive at age &lt; 5 years but less sensitive and
        specific as age increases
      </li>
      <li>Myalgia, headache, photophobia</li>
      <li>
        <b>Hoarseness</b> (Chlamydia pneumonia) and <b>wheezing</b> a child older than 5
        years (Mycoplasma or Chlamydia) suggest atypical pneumonia
      </li>
      <li>
        Upper lobe pneumonias may present with a clinical picture suggestive
        of meningitis
      </li>
      <li>
        Lower lobe pneumonias may present as vague abdominal pain mimicking
        appendicitis
      </li>
      <li>
        It is virtually impossible to clinically differentiate bacterial from
        viral pneumonia except that bacterial pneumonia might have a more
        abrupt and severe onset after days of symptoms of an upper respiratory
        tract infection.
      </li>
    </ul>

    <div class="border-btm"></div>

    <p class="cpg-headers">INVESTIGATIONS</p>
    <p class="cpg-sub-headers">Chest radiographs</p>
    <ul>
      <li>Patients 4 years and above posteroanterior upright position</li>
      <li>Patients less than 4 years supine anteroposterior position</li>
      <li>Lateral view is preferred if lobar pneumonia is present</li>
      <li>
        Decubitus position for effusion or empyema (Ultrasound my give better
        information)
      </li>
      <li>Follow-up chest radiographs not routinely indicated</li>
      <li>Follow-up radiographs are indicated in</li>
      <ul>
        <li>Complicated pneumonias that are clinically unstable</li>
        <li>
          Patients receiving adequate antibiotic coverage for 48-72 hours with
          poor clinical improvement or worsening
        </li>
        <li>
          Recurrent pneumonias that involve the same lobe to rule out a
          suspected anomaly, chest mass, or foreign body
        </li>
      </ul>
    </ul>

    <p class="cpg-sub-headers">Ultrasonography</p>
    <ul>
      <li>Specificity of ultrasonography reach to 97% in children with
        consolidation greater than 1 cm by chest radiographs</li>
      <li>Effusion or empyema</li>
    </ul>

    <p class="cpg-sub-headers">Blood investigations</p>
    <ul>
      <li>Complete blood cell count with differential:(Does not allow differentiation among bacterial, atypical, or
        viral)</li>
      <li>Acute phase reactants (CRP and serum procalcitonin): (Should not be routinely measured)</li>
      <li>Serum electrolytes</li>
      <ul>
        <li>
          Assess dehydration and to rule out hyponatremia secondary to syndrome
          of inappropriate antidiuretic hormone secretion.
        </li>
        <li>Not routinely indicated in the outpatient setting</li>
      </ul>
    </ul>

    <p class="cpg-sub-headers">Blood cultures</p>

    <ul>
      <li>
        Not routinely indicated children who have nontoxic effects and fully
        immunized
      </li>
      <li>Yield only positive in 10-12% of children</li>
      <li>
        In patients with parapneumonic effusion or empyema the yield increases
        to 30-40%.
      </li>
      <li>
        Follow-up blood cultures are not necessary in patients with clear
        improvement
      </li>
    </ul>

    <p class="cpg-sub-headers">Laboratory Findings in Empyema</p>

    <ul>
      <li>pH &lt;7.1</li>
      <li>Glucose &lt;40 mg/dL</li>
      <li>Lactate dehydrogenase >1000 IU/mL</li>
    </ul>

    <div class="border-btm"></div>
    <p class="cpg-headers">HOSPITALIZATION INDICATIONS</p>
    <ul>
      <li>Hypoxia (oxygen saturations &lt; 90-92%) </li>
      <li>Infants &lt;3-6 months with suspected bacterial infection</li>
      <li>Tachypnea:</li>
      <ul>
        <li>Infants &lt;12 months of age: respiratory rate >70 breaths/min</li>
        <li>Children: respiratory rate >50 breaths/min</li>
      </ul>
      <li>
        Respiratory distress: apnea, grunting, difficulty breathing, and poor
        feeding
      </li>
      <li>Signs of dehydration</li>
      <li>Inability to maintain hydration or oral intake</li>
      <li>Capillary refill time >2 seconds</li>
      <li>
        Infants and children with toxic appearance or suspected or confirmed
        to have infection with a virulent organism (CA-MRSA or group A
        Streptococcus)
      </li>
      <li>Underlying conditions comorbidities that:</li>
      <ul>
        <li>
          May predispose patients to a more serious course (e.g.,
          cardiopulmonary disease, genetic syndromes, neurocognitive disorders)
        </li>
        <li>May be worsened by pneumonia (e.g., metabolic disorder)</li>
        <li>
          May adversely affect response to treatment (e.g., immunocompromised
          host, sickle cell disease)
        </li>
      </ul>
      <li>Complications (e.g., effusion/empyema)</li>
      <li>Failure of outpatient therapy (48-72 hours with no response)</li>
      <li>
        Caretaker unable to provide appropriate observation or to comply with
        prescribed home therapy
      </li>
    </ul>
    <div class="border-btm"></div>
    <p class="cpg-headers">INDICATIONS FOR ICU ADMISSION</p>

    <ul>
      <li>
        Severe respiratory distress or impending respiratory failure requiring
      </li>
      <ul>
        <li>Intubation and mechanical ventilation</li>
        <li>Positive pressure ventilation</li>
      </ul>
      <li>Recurrent apnea or slow irregular respirations</li>
      <li>
        Cardiopulmonary monitoring due to cardiovascular compromise secondary
        to:
      </li>
      <ul>
        <li>Sustained tachycardia</li>
        <li>Inadequate blood pressure</li>
      </ul>
      <li>Requires pharmacologic support of blood pressure or perfusion</li>
      <li>Altered mental status due to hypercarbia or hypoxemia</li>
      <li>Pediatric Early Warning Score >6</li>
    </ul>

    <div class="border-btm"></div>
    <p class="cpg-headers">TREATMENT</p>
    <p class="cpg-sub-headers">Supportive care</p>

    <ul>
      <li>Antipyretics</li>
      <li>Suctioning</li>
      <li>Hydration</li>
      <li>
        Mucolytics and cough suppressants have no role in the treatment of
        pneumonia
      </li>
      <li>
        Zinc supplementation (in case of recurrent severe pneumonia in
        children &lt; 5 years with evidence of zinc deficiency)
      </li>
      <li>
        Chest physiotherapy: There is no evidence that its beneficial in the
        management of pneumonia or leads to a decrease in the length of stay
        or a change in the outcome
      </li>
    </ul>

    <p class="cpg-sub-headers">Outpatient Antibiotics</p>
    <ul>
      <li>
        Amoxicillin or amoxicillin-clavulanate the most appropriate first-line
        antimicrobial agent because S pneumonia remains the most commonly
        implicated pathogen
      </li>
      <li>High doses (90-100 mg/kg daily) may overcome resistance</li>
      <li>
        Macrolide (azithromycin or clarithromycin) in school-aged children and
        teens with a clinical picture compatible with atypical CAP
      </li>
    </ul>

    <p class="cpg-sub-headers">Inpatient Antibiotics</p>
    <ul>
      <li>
        Based on antibiogram of the hospital mainly regarding S pneumonia
      </li>
      <li>Amoxicillin (80-90 mg/kg/24 hr)</li>
      <li>Cefuroxime axetil</li>
      <li>Amoxicillin/clavulanate</li>
      <li>
        Third-generation cephalosporin (cefotaxime at 200 mg/kg daily) used in
      </li>
      <ul>
        <li>Infants and children who are not fully immunized</li>
        <li>Penicillin-resistant pneumococcal strains</li>
        <li>Infants and children with severe life-threatening infections</li>
        <li>Pneumonia complications, such as empyema.</li>
      </ul>
      <li>
        Macrolides (Oral or parenteral) in patients with suspected Mycoplasma
        pneumoniae
      </li>
      <li>
        Vancomycin, linezolid, or clindamycin if clinical or radiographic
        findings suggestive of Staph aureus
      </li>
      <li>
        Children proved to be allergic to B-lactams, you can use carbapenems
        (meropenem, 20-40 mg/kg per dose every 8 hours), or Fluoroquinolones
        (eg, levofloxacin, moxifloxacin)
      </li>
      <li>
        Anaerobes coverage in cases of lung abscess or aspiration pneumonia
      </li>
    </ul>

    <table class="cpg-table">
      <tr>
        <th style="background: #f4b083">Outpatient</th>
        <th style="background: #f4b083">Inpatient</th>
      </tr>
      <tr>
        <td style="background: #c9c9c9">
          <b>First line</b> <br />
          Young children: Amoxicillin<br />
          Adolescent: Azithromycin
        </td>
        <td style="background: #c9c9c9">
          <b>First line</b> <br />
          Ampicillin or amoxicillin<br />
          Cephalosporin + Azithromycin
        </td>
      </tr>
      <tr>
        <td style="background: #ffe599">
          <b>Second line (adolescent)</b> <br />
          Macrolide or doxycycline<br />
          Fluoroquinolones (eg, levofloxacin, moxifloxacin)
        </td>
        <td style="background: #ffe599">
          <b>Second line</b> <br />
          Vancomycin<br />Clindamycin<br />Linezolid<br />
        </td>
      </tr>
    </table>
    <br />
    <p class="cpg-sub-headers">Duration of treatment</p>
    <ul>
      <li>
        Uncomplicated total duration 7-10 days (parenteral and oral therapy)
      </li>
      <li>Two weeks or more in complicated cases</li>
      <li>
        If No clinical improvement or deterioration of the clinical picture
        after adequate antibiotic coverage for 48-72 hours do further
        investigation to rule out alternative diagnosis (foreign body),
        antibiotic resistance, or complicated pneumonia.
      </li>
    </ul>

    <div class="border-btm"></div>
    <p class="cpg-headers">DISCHARGE CRITERIA</p>

    <ul>
      <li>Clinical improvement in the level of activity and appetite</li>
      <li>Decreased fever for at least 12- 24 hours.</li>
      <li>
        Sustained pulse oximetry measurements greater than 90% in room air for
        at least 12 to 24 hours.
      </li>
      <li>Stable and/or baseline mental and cardiorespiratory status</li>
      <li>
        Ability to tolerate their home anti-infective regimen and the
        caretaker at home has the ability to administer therapy
      </li>
      <li>Ability to maintain adequate fluid and nutrition orally</li>
      <li>
        Chest tube must have been discontinued 12-24 hours before discharge
        with no clinical evidence of deterioration
      </li>
    </ul>

  </div>
  <script src="/js/header.js"></script>
</body>

</html>